Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 60/100

Failure Rate

37.5%

3 terminated/withdrawn out of 8 trials

Success Rate

40.0%

-46.5% vs industry average

Late-Stage Pipeline

50%

4 trials in Phase 3/4

Results Transparency

100%

2 of 2 completed trials have results

Key Signals

1 recruiting2 with results

Enrollment Performance

Analytics

Phase 2

3(37.5%)

Phase 4

3(37.5%)

Phase 3

1(12.5%)

Phase 1

1(12.5%)

8Total

Phase 2(3)

Phase 4(3)

Phase 3(1)

Phase 1(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (8)

Showing 8 of 8 trials

NCT01718301Phase 3Terminated

HIV Patients With Chronic Hepatitis C Genotype 1 Infection Who Failed Previously to Peginterferon /Ribavirin

Role: lead

NCT01778413Phase 4Completed

Virological and Immunological Safety of a Dose Reduction Strategy Antiretroviral Regimen With Efavirenz / Tenofovir / Emtricitabine

Role: lead

NCT04971577Phase 2Recruiting

Efficacy of Simvastatin in Alcoholic Liver Fibrosis

Role: lead

NCT04483674Phase 2Unknown

Bictegravir/FTC/TAF for the Treatment of Primary HIV Infection

Role: lead

NCT04261179Phase 4Unknown

Study Comparing Lymphoseek® vs. Albumin Nanocolloid in Head and Neck, Melanoma and Breast Cancer

Role: lead

NCT01587222Phase 2Withdrawn

Midodrine, Octreotide and Albumin: Impact on Renal Function of Patients With Liver Cirrhosis and Renal Failure

Role: lead

NCT02109315Phase 1Withdrawn

Vitamin C and Liraglutide Effects on Hypoglycemia-induced Oxidative Stress, Inflammation and Endothelial Dysfunction in Type 1 Diabetes.

Role: lead

NCT01785043Phase 4Completed

Differences in Endothelial Function Amongst Sitagliptin and Liraglutide Users

Role: lead

All 8 trials loaded